Predicting the Susceptibility of Meningococcal Serogroup B Isolates to Bactericidal Antibodies Elicited by Bivalent rLP2086, a Novel Prophylactic Vaccine

Bivalent rLP2086 (Trumenba), a vaccine for prevention of Neisseria meningitidis serogroup B (NmB) disease, was licensed for use in adolescents and young adults after it was demonstrated that it elicits antibodies that initiate complement-mediated killing of invasive NmB isolates in a serum bacterici...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:mBio
Autors principals: McNeil, Lisa K., Donald, Robert G. K., Gribenko, Alexey, French, Roger, Lambert, Nathaniel, Harris, Shannon L., Jones, Thomas R., Li, Sheng, Zlotnick, Gary, Vogel, Ulrich, Claus, Heike, Abad, Raquel, Vazquez, Julio A., Borrow, Ray, Findlow, Jamie, Taha, Muhamed-Kheir, Deghmane, Ala-Eddine, Caugant, Dominique A., Kriz, Paula, Musilek, Martin, Wang, Xin, Vuong, Jeni, Mayer, Leonard W., Pride, Michael W., Jansen, Kathrin U., Anderson, Annaliesa S.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5850321/
https://ncbi.nlm.nih.gov/pubmed/29535195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/mBio.00036-18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars